清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer

医学 肺癌 酪氨酸激酶 癌症研究 蛋白酪氨酸激酶 酪氨酸激酶抑制剂 激酶 癌症 受体酪氨酸激酶 呼吸道疾病 肿瘤科 原癌基因酪氨酸蛋白激酶Src 布鲁顿酪氨酸激酶
作者
Beung‐Chul Ahn,Yu Jung Kim,Young Ju Lee,Koung Jin Suh,Se Hyun Kim,Dong-Wan Kim,Tae Min Kim,Ki Hyeong Lee,Ji‐Youn Han
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:12 (1): 84-84 被引量:5
标识
DOI:10.1001/jamaoncol.2025.5097
摘要

Importance: ROS1 rearrangement is rare but is an attractive therapeutic target in advanced non-small cell lung cancer (NSCLC). Crizotinib, entrectinib, and repotrectinib have been approved by the US Food and Drug Administration for treatment of ROS1-positive NSCLC. Lorlatinib, a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI), targets ROS1 and ALK; however, its efficacy and safety for patients with advanced ROS1-positive remains unknown. Objective: To evaluate the efficacy and safety of lorlatinib for patients with advanced ROS1-positive NSCLC never treated with any TKI. Design, Setting, and Participants: This multicenter phase 2 nonrandomized clinical trial enrolled patients with advanced ROS1-positive NSCLC who were TKI-naive with an Eastern Cooperative Oncology Group performance status of 2 or less, and 1 or no prior platinum-based chemotherapy. Participants were recruited from June 2019 to April 2023 and followed up through August 2024. Data analysis was performed from April 5 to August 30, 2025. Interventions: Lorlatinib, 100 mg daily, was administered until disease progression, toxic effects, consent withdrawal, or death. Main Outcomes and Measures: Objective response rate (ORR). Secondary end points were progression-free survival (PFS), overall survival, and safety. Results: The analysis included 32 patients (mean [IQR] age, 59 [11] years; 20 female [63%] and 12 male [37%] individuals), all of whom had adenocarcinoma histologic findings. There were 21 patients (66%) who were treatment-naive, and 11 (34%) who had prior chemotherapy. The median (SD) follow-up duration was 22.1 (15.4-46.8) months; ORR was 73% (95% CI, 56%-86%; 22 of 30 patients), and disease control rate was 90% (95% CI, 74%-97%; 27 of 30 patients). Median (IQR) PFS was 53.6 (95% CI, 27.8-79.5) months, and overall survival was not reached. For treatment-naive vs previously treated patients, the ORR was 90% vs 60%, and PFS was not reached vs 35.8 months. Grade 3 to 4 adverse effects were hypertriglyceridemia (5 patients [16%]) and hypercholesterolemia (8 patients [25%]). No treatment-related deaths occurred. Conclusions and Relevance: In this nonrandomized clinical trial, lorlatinib demonstrated durable efficacy and manageable safety in TKI-naive advanced ROS1-positive NSCLC, supporting the potential for using lorlatinib in earlier treatment settings. Trial Registration: ClinicalTrials.gov Identifier: NCT03612154.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彩色的芷容完成签到 ,获得积分10
刚刚
谦让康完成签到 ,获得积分10
1秒前
朱洪帆完成签到,获得积分20
14秒前
靓丽的伟祺完成签到,获得积分10
26秒前
从容的凡旋完成签到,获得积分10
28秒前
Jun的应助被朱洪帆采纳,获得10
29秒前
无私的碧玉完成签到,获得积分10
33秒前
果酱完成签到,获得积分10
33秒前
万能图书馆的应助被无限幻枫采纳,获得10
34秒前
36秒前
Maestro_S的应助被朱洪帆采纳,获得10
37秒前
40秒前
KalEl发布了新的文献求助10
40秒前
Zhangym完成签到 ,获得积分10
46秒前
安静的傲松完成签到,获得积分10
55秒前
null的应助被科研通管家采纳,获得10
59秒前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
欢喜映阳完成签到,获得积分10
1分钟前
开心恶天完成签到,获得积分10
1分钟前
zjh123完成签到,获得积分10
1分钟前
lily完成签到 ,获得积分10
1分钟前
1分钟前
xuxu213完成签到,获得积分20
1分钟前
1分钟前
无限幻枫发布了新的文献求助10
1分钟前
顺利的三德完成签到,获得积分10
1分钟前
华无剑的应助被xuxu213采纳,获得10
1分钟前
和谐的小懒虫完成签到,获得积分10
1分钟前
李思雨完成签到 ,获得积分10
1分钟前
苗条的之桃完成签到,获得积分10
1分钟前
无辜的凝安完成签到,获得积分10
1分钟前
李成恩完成签到 ,获得积分10
1分钟前
Bill02完成签到 ,获得积分10
1分钟前
外向的香岚完成签到,获得积分10
1分钟前
Xuezhuoxin完成签到,获得积分10
1分钟前
2分钟前
幸福的冰双完成签到,获得积分10
2分钟前
悲凉的丝完成签到,获得积分10
2分钟前
年轻的幼菱完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159011
求助须知:如何正确求助?哪些是违规求助? 9554538
关于积分的说明 21719449
捐赠科研通 7748505
什么是DOI,文献DOI怎么找? 3427122
关于科研通互助平台的介绍 2552015
邀请新用户注册赠送积分活动 2471370